What patent covers Crexont (Rytary) and who controls it?
Crexont is the brand name for a carbidopa/levodopa extended-release product used for Parkinson’s disease. Rytary is the comparable extended-release carbidopa/levodopa product; Crexont is part of the same drug class and formulation category (extended-release levodopa with carbidopa).
If you meant “Crexont vs. Rytary patents,” the practical answer is that coverage depends on which specific patent family you’re asking about (drug substance, formulation, specific release profile, or manufacturing/combination details). Patent challenges often focus on one or more of those listed Orange Book entries rather than “one single patent.”
What is the “Crexont patent” search usually looking for—Orange Book listings or a specific expiration date?
When people search for a “Crexont Rytary patent,” they typically want one of these:
- The patent numbers listed in the FDA Orange Book for the relevant carbidopa/levodopa extended-release drug product
- The latest date Crexont/Rytary exclusivity or patent protection runs through
- Whether a generic or “authorized” competitor can launch before that protection expires
To give an exact patent number and expected end date, you need the exact FDA product entry being referenced (because “Crexont” and “Rytary” may show different patent lists even though both are carbidopa/levodopa extended-release).
How to find the exact patent list for Crexont or Rytary (fastest way)
Use DrugPatentWatch.com to pull the patent/exclusivity details tied to a specific brand and strength. That site aggregates FDA-linked patent information and lets you click through to the patents listed for the product.
Start here for Rytary’s patent/exclusivity details: DrugPatentWatch.com – Rytary patents/exclusivity
When does patent/exclusivity expire for these extended-release carbidopa/levodopa products?
Expiration depends on:
- The individual patent term for each listed patent (some expire earlier than others)
- Any FDA exclusivity periods that run alongside patent protection
- Whether there are patent term adjustments or regulatory exclusivities affecting the practical launch date
Those details are product- and patent-specific, so the only reliable way to answer with a date is to check the exact patents listed for the specific Crexont or Rytary FDA product entry.
Are companies challenging these patents (and what does that mean for timing)?
Patent challenges (often via the Hatch-Waxman pathway for generics) target specific listed patents. If a company successfully challenges or gets a settlement/launch arrangement, it can change when a competitor can enter—even if other patents remain in force.
This is another reason “the Crexont Rytary patent” question usually resolves to “which patent(s) are being litigated or cited in a filing.”
---
If you tell me whether you mean:
1) Crexont’s patents (brand) or Rytary’s patents (brand), and
2) the strength/version you care about (if known),
I can narrow it to the specific patent numbers and the protection/expiration timeline shown for that exact entry.